Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SYNCHRONIZE-CVOT

SYNCHRONIZE-CVOT

Survodutide · Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Survodutide
Population
Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), obesity
Official title
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Sponsor
Boehringer Ingelheim
Phase
3
Registry status
completed · 2023-11 → 2026-06
Participants
5530
Duration
72 weeks
Registry
NCT06077864

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
survodutide 3.6 mgobesity72——−9.3 % vs −2.4 %
Δ −6.9 pp
—28.2 vs 11.144.0 vs 41.048.0 vs 12.131.7 vs 4.822.5 vs 23.9−4.3 vs −1.7verified
survodutide 6.0 mgobesity72——−9.7 % vs −2.4 %
Δ −7.3 pp
—29.1 vs 11.143.4 vs 41.049.0 vs 12.134.0 vs 4.820.8 vs 23.9−4.9 vs −1.7verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (14)
  • survodutide 3.6 mg · weight_tp · Table 3
    Mean change in bodyweight −9·3% −9·7% −2·4%
  • survodutide 3.6 mg · ae_dc · Table 4
    Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
  • survodutide 3.6 mg · disc_any · Results, paragraph 2 (also Figure 1)
    807 (44·0%) participants in
  • survodutide 3.6 mg · nausea · Table 4
    Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
  • survodutide 3.6 mg · vomiting · Table 4
    Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
  • survodutide 3.6 mg · sae · Table 4
    Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
  • survodutide 3.6 mg · sbp · Table 2
    Survodutide 3·6 mg: absolute change 1836 −4·29 1836 −1·72
  • survodutide 6.0 mg · weight_tp · Table 3
    Mean change in bodyweight −9·3% −9·7% −2·4%
  • survodutide 6.0 mg · ae_dc · Table 4
    Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
  • survodutide 6.0 mg · disc_any · Results, paragraph 2 (also Figure 1)
    796 (43·4%) in the
  • survodutide 6.0 mg · nausea · Table 4
    Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
  • survodutide 6.0 mg · vomiting · Table 4
    Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
  • survodutide 6.0 mg · sae · Table 4
    Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
  • survodutide 6.0 mg · sbp · Table 2
    Survodutide 6·0 mg: absolute change 1835 −4·89 1836 −1·72

Cardiovascular and kidney outcomes

SYNCHRONIZE-CVOT survodutide 3.6 or 6.0 mg once weekly (pooled) vs placebo · Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD) · n = 5530 · 2026 verified

EndpointHR95 % CIEvents, drug vs controlStatus
Expanded MACE primary
Primary endpoint: five-point MACE = time to first CV death, non-fatal stroke, non-fatal MI, ischaemia-related coronary revascularisation, or heart failure event (HHF, ED visit, urgent care visit or urgent outpatient HF visit); non-inferiority margin 1.65
0.890.67–1.18136 vs 76verified
3-point MACE
Key secondary: three-point MACE = CV death, non-fatal stroke, non-fatal MI (non-inferiority vs placebo)
0.840.60–1.1888 vs 52verified
4-point MACE
Four-point MACE as defined by the trial = CV death, non-fatal stroke, non-fatal MI, or ischaemia-related coronary revascularisation
0.930.67–1.29103 vs 55verified
Cardiovascular death
Adjudicated death from cardiovascular causes (component of primary endpoint)
1.050.49–2.2321 vs 10verified
All-cause death
All-cause mortality
1.200.73–1.9753 vs 22verified
Myocardial infarction
Adjudicated non-fatal myocardial infarction — non-fatal events only
0.990.60–1.6446 vs 23verified
Stroke
Adjudicated non-fatal stroke — non-fatal events only
0.720.41–1.2729 vs 20verified
Heart failure event
Heart failure event, broader than hospitalisation alone: hospitalisation, emergency department visit, urgent care visit or urgent outpatient heart failure visit (adjudicated). CV death or hospitalisation for HF: HR 0.86 (0.55–1.35).
0.760.46–1.2540 vs 26verified
CV death or worsening HF
First occurrence of adjudicated CV death or adjudicated heart failure event (HF event incl. HHF, ED/urgent visits)
0.800.52–1.2256 vs 35verified
Coronary revascularisation
Adjudicated ischaemia-related coronary revascularisation
2.490.85–7.3020 vs 4verified
New-onset diabetes
Onset of (protocol-defined) type 2 diabetes in participants without type 2 diabetes at baseline
0.280.16–0.5018 vs 32verified
Verbatim quotes (11)
  • Expanded MACE · Table 2, primary composite endpoint row, p 8
    Pooled survodutide: primary composite 136 (3·7%) 2·15 76 (4·1%) 2·42 0·89 ·· ·· <0·0001 endpoint (five-point MACE)* (non- (0·67 to 1·18)†
  • 3-point MACE · Table 2, key secondary endpoints, p 8
    Pooled survodutide: three-point 88 (2·4%) 1·38 52 (2·8%) 1·64 0·84 ·· ·· <0·0001 MACE (non-inferiority vs placebo)‡ (0·60 to 1·18)
  • 4-point MACE · Table 2 (continued), other secondary endpoints, p 9
    First occurrence of any adjudicated 103 (2·8%) 1·62 55 (3·0%) 1·74 0·93 ·· ·· NA component of four-point MACE§ (0·67 to 1·29)
  • Cardiovascular death · Table 2, primary endpoint components, p 8
    Death from cardiovascular causes 21 (0·6%) 0·32 10 (0·5%) 0·30 1·05 ·· ·· NA (0·49 to 2·23)
  • All-cause death · Table 2 (continued), other secondary endpoints, p 9
    All-cause mortality 53 (1·4%) 0·80 22 (1·2%) 0·67 1·20 ·· ·· NA (0·73 to 1·97)
  • Myocardial infarction · Table 2, primary endpoint components, p 8
    Non-fatal myocardial infarction 46 (1·3%) 0·72 23 (1·3%) 0·72 0·99 ·· ·· NA (0·60 to 1·64)
  • Stroke · Table 2, primary endpoint components, p 8
    Non-fatal stroke 29 (0·8%) 0·45 20 (1·1%) 0·63 0·72 ·· ·· NA (0·41 to 1·27)
  • Heart failure event · Table 2, primary endpoint components, p 8
    Heart failure event† 40 (1·1%) 0·63 26 (1·4%) 0·82 0·76 ·· ·· NA (0·46 to 1·25)
  • CV death or worsening HF · Table 2 (continued), other secondary endpoints, p 9
    First occurrence of adjudicated death 56 (1·5%) 0·88 35 (1·9%) 1·10 0·80 ·· ·· NA from cardiovascular causes or (0·52 to 1·22)
  • Coronary revascularisation · Table 2, primary endpoint components, p 8
    Ischaemia-related coronary 20 (0·5%) 0·31 4 (0·2%) 0·12 2·49 ·· ·· NA revascularisation (0·85 to 7·30)
  • New-onset diabetes · Table 2 (continued), other secondary endpoints, p 9
    Onset of type 2 diabetes in 18 (1·1%) 0·60 32 (3·6%) 2·10 0·28 ·· ·· NA participants without type 2 diabetes (0·16 to 0·50)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SYNCHRONIZE-CVOT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-cvot/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.